Maysiglu (Sitagliptin)

Sitagliptin works by selectively blocking the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises the levels of the incretin hormones GLP‑1 and GIP, which increase insulin secretion, reduce glucagon release, and slow gastric emptying in a glucose‑dependent manner, thereby improving overall glycemic control.

The dosage of Maysiglu is individualized by the prescribing healthcare professional based on the patient’s renal function, glycemic targets, and concomitant therapies. Patients should follow the exact dosing instructions provided by their prescriber and not adjust the dose on their own.

The safety of sitagliptin in pregnancy and lactation has not been definitively established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician before use.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Maysiglu. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maysiglu (sitagliptin) belongs to the DPP‑4 inhibitor class, which generally offers a lower risk of hypoglycemia compared with sulfonylureas and does not cause weight gain. Compared with GLP‑1 receptor agonists, sitagliptin is oral, easier to administer, but may be less potent in reducing HbA1c.

Maysiglu should be stored at room temperature, below 25 °C, in its original blister pack or container. Protect the tablets from moisture, direct sunlight and excessive heat to maintain stability throughout its shelf life.

Maysiglu is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

The most serious adverse events to monitor are acute pancreatitis, severe allergic reactions such as angioedema or Stevens‑Johnson syndrome, and persistent joint pain (arthralgia). Patients should seek immediate medical attention if they experience severe abdominal pain, swelling of the face or throat, or unexplained joint discomfort.

Maysiglu is contraindicated in individuals with a known hypersensitivity to sitagliptin or any component of the formulation. It should also be avoided in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) unless dose‑adjusted by a specialist, and in those with a history of pancreatitis.